Exhibit 99.1 TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update · Reported revenues of $5.7 million in 4Q23, up 77$18.5 million, up 49% over prior year · Gross Margin of 90% in 4Q23 and 86% for full year · CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code · Real-world data published on TriNav system demonstrating significant improvement in the delivery of therapeutics to liver tumors for patients with ...